Short answer
ADMA BIOLOGICS, INC. (ADMA) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $114M (down 0.3% year over year) with net income of $45M.
Q1 2026 key financials · XBRL
- Revenue
- $114M
- −0.3% YoY
- Net income
- $45M
- +68.5% YoY
- Operating margin
- 50.9%
- Gross margin
- 70.5%
- EPS (diluted)
- $0.19
- +72.7% YoY
Source: XBRL data from the ADMA BIOLOGICS, INC. (ADMA) Q1 2026 10-Q on SEC EDGAR. USD.
ADMA BIOLOGICS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $114.5M, down $0.3M or 0.3% YoY
- Gross margin 70.5% vs 53.2% YoY; net income $45.3M vs $26.9M
- Best performer ASCENIV revenue $97.5M, up 27.7%; BIVIGAM $15.4M, down 54.0%
- Cash $138.2M vs $87.6M at December 31, 2025; inventory $222.1M vs $206.5M
- Outlook: ASCENIV growth expected throughout 2026; competitive pricing may pressure BIVIGAM and future results
Risk Factors
- New AI-related risk factor, triggered by emerging artificial-intelligence use and associated reputational harm or liability exposure
- Profitability risk: 2025 net income $146.9 million versus $197.7 million in 2024, with accumulated deficit $161.7 million
- FDA inspection risk: Form 483 observations or warning letters could restrict facilities, trigger recalls, or disrupt product supply
- Supply-chain risk: third-party fill-finishers and plasma suppliers may fail to deliver materials meeting specifications or required quantities
- Financial risk: JPMorgan credit facility permits acceleration and collateral seizure under specified circumstances
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ADMA BIOLOGICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.